Similar articles for PMID: 10555124

Year	Number of Results
1981	1
1982	1
1983	1
1984	1
1985	3
1986	6
1987	2
1988	5
1989	3
1990	4
1991	4
1992	2
1993	5
1994	7
1995	7
1996	5
1997	7
1998	5
1999	6
2000	4
2001	5
2002	6
2003	2
2004	3
2006	3
2007	1
2009	1
2011	2
2012	2
2013	1
2015	1
2024	0

1

Phase I clinical and pharmacokinetic study of an one-hour infusion of ormaplatin (NSC 363812).

Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB, Feierabend C, Robins HI, Spriggs DR, Wilding G. Tutsch KD, et al. Invest New Drugs. 1999;17(1):63-72. doi: 10.1023/a:1006223100561. Invest New Drugs. 1999. PMID: 10555124 Clinical Trial.

2

Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule.

Schilder RJ, LaCreta FP, Perez RP, Johnson SW, Brennan JM, Rogatko A, Nash S, McAleer C, Hamilton TC, Roby D, et al. Schilder RJ, et al. Cancer Res. 1994 Feb 1;54(3):709-17. Cancer Res. 1994. PMID: 8306332 Clinical Trial.

3

Phase I clinical trial of ormaplatin (tetraplatin, NSC 363812).

O'Rourke TJ, Weiss GR, New P, Burris HA 3rd, Rodriguez G, Eckhardt J, Hardy J, Kuhn JG, Fields S, Clark GM, et al. O'Rourke TJ, et al. Anticancer Drugs. 1994 Oct;5(5):520-6. doi: 10.1097/00001813-199410000-00002. Anticancer Drugs. 1994. PMID: 7858283 Clinical Trial.

4

Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.

Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N. Sasaki Y, et al. Cancer Res. 1991 Mar 1;51(5):1472-7. Cancer Res. 1991. PMID: 1997185 Clinical Trial.

5

Phase I and pharmacokinetic study of intraperitoneal ormaplatin.

Plaxe SC, Braly PS, Freddo JL, McClay E, Christen RD, Kirmani S, Kim S, Heath D, Howell SB. Plaxe SC, et al. Gynecol Oncol. 1993 Oct;51(1):72-7. doi: 10.1006/gyno.1993.1249. Gynecol Oncol. 1993. PMID: 8244179 Clinical Trial.

6

Pharmacokinetic and biotransformation studies of ormaplatin in conjunction with a phase I clinical trial.

Petros WP, Chaney SG, Smith DC, Fangmeier J, Sakata M, Brown TD, Trump DL. Petros WP, et al. Cancer Chemother Pharmacol. 1994;33(4):347-54. doi: 10.1007/BF00685911. Cancer Chemother Pharmacol. 1994. PMID: 8281629 Clinical Trial.

7

Pharmacokinetics and biotransformations of oxaliplatin in comparison with ormaplatin following a single bolus intravenous injection in rats.

Luo FR, Wyrick SD, Chaney SG. Luo FR, et al. Cancer Chemother Pharmacol. 1999;44(1):19-28. doi: 10.1007/s002800050940. Cancer Chemother Pharmacol. 1999. PMID: 10367745

8

Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.

Figg WD, Christian MC, Lush R, Link CJ, Davis P, Kohn E, Sarosy G, Rothenberg ML, Weiss RB, Ryan N, Jacobs J, Reed E. Figg WD, et al. Biopharm Drug Dispos. 1997 May;18(4):347-59. doi: 10.1002/(sici)1099-081x(199705)18:4<347::aid-bdd23>3.0.co;2-o. Biopharm Drug Dispos. 1997. PMID: 9158882 Clinical Trial.

9

Phase I clinical and pharmacokinetic study of the oral platinum analogue JM216 given daily for 14 days.

Sessa C, Minoia C, Ronchi A, Zucchetti M, Bauer J, Borner M, de Jong J, Pagani O, Renard J, Weil C, D'Incalci M. Sessa C, et al. Ann Oncol. 1998 Dec;9(12):1315-22. doi: 10.1023/a:1008441416790. Ann Oncol. 1998. PMID: 9932162 Free article. Clinical Trial.

10

Possible correlation between ormaplatin biotransformations and neurotoxicity.

Sakata M, Chaney SG, Spriggs DR. Sakata M, et al. Oncol Res. 1995;7(2):67-71. Oncol Res. 1995. PMID: 7579729

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

104 results

Results by year